ArticleCancer immunology, immunotherapy : CII2009
Vaccination strategies in patients with renal cell carcinoma.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.PloS one · 2011Pooled it
- Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma.Frontiers in immunology · 2021Review
- Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.International journal of nanomedicine · 2019Review
- Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?Clinical & experimental metastasis · 2013Article
- Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.Experimental and therapeutic medicine · 2012Article
- Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2012Article
- Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse.Immunologic research · 2012Article
- The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.Seminars in oncology · 2012Review
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.International journal of cancer · 2012Article
- Update on vaccine development for renal cell cancer.Open access journal of urology · 2010Review
- Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.Cancer immunology, immunotherapy : CII · 2010Article
- Advances in cellular therapy for the treatment of thyroid cancer.Journal of oncology · 2010Article
- Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.Cancer cell & microenvironmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although new treatment options for patients with advanced renal cell cancer (RCC) have been developed within recent years, vaccination is still a promising emerging treatment option. An increasing number of tumor-associated antigens (TAA) available for RCC are currently used and analyzed for their efficacy for antigen-specific vaccine strategies. Recently, antigen-specific vaccination with dendritic cells in patients with metastatic RCC was shown to induce cytotoxic T cell response associated with objective clinical responses in some of the patients. Furthermore, current studies focus on the development of more effective vaccine regimes, such as the application of polyvalent, HLA-independent RNA coding for multiple TAA and adjuvants. First results demonstrate promising clinical and immunological efficacy. The efficacy of antigen-specific vaccination might be improved by a combination of tyrosine kinase inhibitors, since sunitinib was shown to promote T cell induction following vaccination in a mouse model and elimination of regulatory T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.